Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies

Fig. 4

IHMT-337 inhibits breast cancer cell proliferation by degrading EZH2, a CDK4 transcription factor. a Proliferation studies: Effects of 6-day IHMT-337 treatment on proliferation of TNBC cell lines. EPZ6438 was set as control. b Proliferation studies: Effects of EZH2 knockdown on proliferation of MDA-MB-231 cells. c Cell cycle studies: Effects of IHMT-337 on cell cycle in MDA-MB-231 cell. EPZ6438 was set as control. d The CUT&TAG approach was used on HEK293T and HEK293T EZH2-KO cell lines to determine the sites of EZH2 binding to DNA. e Signaling studies: The inhibitory Effects of 72 h IHMT-337 treatment on cell cycle signaling in MDA-MB-231 cells. EPZ6438 was set as control. f Effects of 72 h IHMT-337 treatment of MDA-MB-231 cells on CDK4 transcriptional level. g Protein levels of EZH2 in HEK239T WT, HEK293T EZH2-KO, and HEK293T SUZ12 KO cells. h Transcriptional level of CDK4 in HEK239T WT, HEK293T EZH2-KO, and HEK293T SUZ12 KO cells

Back to article page